Enanta Pharmaceuticals stock gains 4.48 percent to EUR 11.65
Published on 09/30/2026 at 22:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Enanta Pharmaceuticals stock gained 4.48 percent to EUR 11.65 at Lang & Schwarz on September 30, 2026, versus a prior close of EUR 11.15. The move contrasts with fiscal third-quarter results that missed consensus estimates and keeps the clinical-stage biotechnology company tied to development milestones.
Analyst target remains above price
H.C. Wainwright reiterated a Buy rating and a USD 20.00 price target on September 23, 2026, according to Investing.com. The target is USD 8.35 above the latest Nasdaq price of USD 11.65 cited by the finance quote, although the two prices use different venues and currencies and are not combined into one performance measure.
The broader broker view was also constructive. MarketBeat reported on September 25, 2026, that five analysts held buy ratings and one held a sell rating, producing a Moderate Buy consensus and an average 12-month target of USD 21.00.
Revenue misses by USD 2.40 million
For the fiscal third quarter ended June 30, 2026, Enanta reported revenue of USD 14.36 million and a diluted loss of USD 0.67 per share, according to MarketBeat. Revenue was USD 2.40 million below the USD 16.76 million consensus estimate, while the loss per share exceeded the expected USD 0.51 loss by USD 0.16.
The result makes royalty income and clinical execution the key counterweights for investors. Enanta's investor-relations page identifies RSV programs as a central clinical area and lists its September 1, 2026 investor-conference announcement, including appearances at Baird and H.C. Wainwright events, on the Enanta Pharmaceuticals investor site.
Stock remains below yearly high
Enanta Pharmaceuticals was valued at USD 383.3 million on September 30, 2026. Its primary Nasdaq listing showed a 52-week range of USD 9.91 to USD 17.15, placing the latest US price below the yearly high while the Lang & Schwarz quote captured a 4.48 percent intraday gain.
Enanta Pharmaceuticals stock facts
- Company: Enanta Pharmaceuticals, Inc.
- ISIN: US29251M1062
- Ticker: ENTA
- Primary exchange: NASDAQ
- Price Lang & Schwarz (as of September 30, 2026, 10:27 p.m. CEST): EUR 11.65
- Change versus prior close: plus 4.48 percent
- Prior close Lang & Schwarz (September 29, 2026): EUR 11.15
- Market capitalization: USD 383.3 million (as of September 30, 2026)
- 52-week range: USD 9.91-17.15 (as of September 30, 2026)
- Sector / Industry: Healthcare / Biotechnology
